SLC5A2 and diabetes mellitus: Given that loss-of-function SLC5A2 variants cause glucosuria and pharmacologic induction of glucosuria via SGLT2 inhibition is used to treat diabetes, we hypothesized that SLC5A2 variants will reduce the risk of diabetes.